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Objectives. The purpose of this study was to investigate he role 
of platelet prostacyclin receptor desensitization i  platelet- 
endothelial cell adhesion. 
Background. Platelet-endothelial cel adhesion is regulated by 
endothelial cell-derived mediators, such as prostacyclin and 
endothelium-derived r laxing factor. Prostacyclin activates plate- 
let adenylate cyclase and augments cyclic adenosine monophos- 
phate formation by way of specific membrane r ceptors. Piatelet 
exposure to prostacyclin or chemically stable analogs results in a 
time- and dose-dependent prostacyclin receptor desensitization as
it occurs during infusion therapy with prostacyclin analogs or in 
pathophysiologic s tuations uch as acute myocardial infarction. 
Methods. Adhesion of washed and radiolabeled human plate- 
lets stimulated with thrombin to cultured umbilical vein endothe- 
lial cells was measured under control conditions and under 
conditions of platelet prostacyclin receptor desensitization i - 
duced by incubation with the prostacyclin analog iloprost (10 to 
100 nmol/liter) for 3 h. 
Results. Thrombin (0.08 to 0.2 U/ml) increased platelet adhe- 
sion in a dose-dependent manner from 2.7 + 0.3% to 6.4 _+ 0.6% 
(mean value -+ SEM). Preincubation of platelets resulted in a 
dose-dependent down-regulation of 3H-iloprost binding up to 
58.8 -+ 6.7% of control platelets with 100 nmol/liter of iloprost. 
Co-incubation of prostacyclin receptor-desensitized platelets 
with endothelial cells resulted in a marked augmentation of 
thrombin-induced a hesion up to 28.6 -+ 4.5%. Approximately the 
same increase in platelet adhesion was seen after complete 
abrogation of endothelial cell prostacyclin synthesis by pretreat- 
ment with aspirin. Comparison of iloprost-induced receptor de- 
sensitization and increased platelet-endothelial ce l adhesion 
indicated a positive correlation. 
Conclusions. Platelet prostacyclin receptor desensitization was 
observed in humans in vivo during acute myocardial infarction or 
during therapeutic administration of prostacyclin analogs. In 
vitro platelet prostacyclin receptor desensitization caused a 
marked augmentation f platelet-endothelial cel adhesion. This 
increase in adhesion might result in an enhanced tendency toward 
thrombus formation in humans. 
(JAm CoU Cardiol 1995;26:800-6) 
During recent years, overwhelming evidence became available 
for the role of endothelial cell products in mediating vessel wall 
thromboresistence. Specifically, prostacyclin and endothelium- 
derived relaxing factor are held responsible for inhibiting 
platelet activity, that is, aggregation and adhesion in the 
immediate vicinity of the vessel wall. Both mediators are 
synthesized de novo on stimulation of endothelial cells and are 
released into the vessel lumen and abluminally. Abluminal 
secretion of prostacyclin is probably not involved in the 
physiologic regulation of vessel tone, but it may have important 
implications in situations of hemodynamic instability such as 
those of operative stress or sepsis (1). In contrast, convincing 
evidence from studies with endothelium-derived r laxing factor 
synthesis inhibitors like N°-monomethyl-L-arginine (L-NMMA) 
or N~°-nitro-L-arginine m thyl ester (L-NAME) arose, indicating 
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that endothelium-derived r laxing factor is primarily involved in 
the regulation of vessel tone and contributes to both systemic and 
pulmonary vascular resistance and to blood pressure (2). 
Prostacyclin acts on platelets through a receptor-mediated 
activation of membrane-bound adenylate cyclase and a consecu- 
tive increase in intracelMar cyclic adenosine monophosphate 
(AMP). An increase in cyclic AMP results in a diminished 
availability of cytoplasmic free calcium ions and an omnipresent 
inhibition of platelet functions. In contrast, endothelium-derived 
relaxing factor acts receptor-independently on platelets and 
causes an increase in cyclic guanosine monophosphate by activat- 
ing soluble guanylate cyclase. In contrast to previous reports (3,4) 
emphasizing the role of prostacyclin inhibiting the adhesion of 
activated platelets to endothelial cells, current work (5-8) has 
focused on the role of endothelium-derived r laxing factor. These 
reports have presented evidence that release of endothelium- 
derived relaxing factor is mainly responsible for the inhibition of 
platelet adhesion to endothelial cells (5-7) and that prostacyclin 
predominantly acts as an inhibitor of platelet-platelet in eractions 
(i.e., aggregation) (8). 
The actions of prostacyclin on platelets have been studied 
with radiolabeled prostacyclin orchemically stable prostacyclin 
©1995 by the American College of Cardiology 0735-1097/95/$9.50 
0735-1097(95 )00264-5 
JACC Vol. 26, No. 3 DARIUS ET AL. 801 
September 1995:800-6 PLATELET PROSTACYCLIN RECEPTOR DESENSITIZATION AND ADHESION 
analogs. After characterization f the supposed prostacyclin 
receptor on platelets (9), convincing evidence (10,11) showed a
rapid decrease in the number of prostacyclin receptors on 
human platelets with exposure to nanomolar concentrations of 
prostacyclin over a period of 2 to 4 h. In clinical situations with 
administration of exogenous prostacyclin or analogs--for ex- 
ample, for the treatment of peripheral arterial occlusive dis- 
ease or in pathophysiologic situations, such as acute myocar- 
dial infarction (12)--a significant down-regulation of platelet 
prostacyclin receptors has been reported. 
Although the decrease in platelet prostacyclin receptor 
density during extended exposure of platelets to prostacyclin s
known, the physiologic onsequences of this desensitization 
process are unknown. Thus, we studied the decrease in 3H- 
iloprost binding to human platelets after incubation with 
iloprost, the influence of receptor down-regulation  platelet 
cyclic AMP formation through adenylate cyclase activation and 
the effects of prostacyclin receptor desensitization  platelet 
adhesion to cultured endothelial cells. Because of the role of 
prostacyclin synthesis in endothelial thromboresistance, we
assessed the effect of thrombin on endothelial prostacyclin 
release and, in some experiments, prevented prostaglandin 
production by cyclooxygenase inhibition. 
Methods  
Endothelial cell culture. Human umbilical vein endothelial 
cells were obtained from umbilical cord veins by digestion with 
0.1% collagenase A dissolved in Hanks' buffered salt solution 
for 15 rain at 37°C modified after the method described by 
Jaffe et al. (13). The harvested cells were cultured in T-25 
flasks (precoated with 0.2% gelatin) in Medium 199 supple- 
mented with 20% fetal calf serum, penicillin (50 IU/ml), 
streptomycin (50 pg/ml), and L-glutamine (2 retool/liter) at 
37°C under 5% carbon dioxide and constant humidity (95%). 
Cultured cells were identified as human umbilical vein endo- 
thelial cells by typical morphologic characteristics and positive 
indirect immunofluorescence staining for yon Willebrand fac- 
tor antigen (14). A monoclonal murine anti-yon Willebrand 
factor antibody (IgG1) was used as the primary antibody and a 
fluorescein thiocyanate (FITC)-labeled anti-gamma-globulin 
antibody from sheep as the secondary antibody (both pur- 
chased from Boehringer-Mannheim, Germany). 
For subculture, human umbilical vein endothelial cells were 
harvested with a solution containing 0.01% ethylenediamine 
tetraacetic acid and 0.125% trypsin. All experiments were 
performed with endothelial cells in the first or second passage. 
The cells were seeded into 12- or 24-well plates with an initial 
density of 50,000 or 25,000 cells/well, respectively, and grown 
to confluence within 5 days. 
Prostacyclin synthesis of human umbilical vein endothelial 
cells was measured under basal conditions in successive pas- 
sages over a period of 24 h on 4 consecutive days within a 
passage and after stimulation with thrombin (0.02 to 2.0 U/ml) 
for 15 rain. After the incubation period, supernatant was 
collected, supplemented with indomethacin (30 t~mol/liter) 
and stored at -20°C until 6-keto-prostaglandin F1~ (PGFI~) 
determination by radioimmunoassay. Results were corrected 
for the number of endothelial cells in each well and expressed 
as 6-keto-PGFl~ release in rig/106 cells per 24 h or ng/106 cells 
per 15 rain, respectively. 
In some experiments human umbilical vein endothelial cells 
were pretreated with aspirin or N°-monomethyl-L-arginine to 
prevent synthesis of the endothelial cell products prostacyclin 
or endothelium-derived r laxing factor. Prostacyclin synthesis 
was inhibited by preincubation with aspirin (1 mmol/liter, 
30 min), endothelium-derived relaxing factor synthesis was 
reduced by preincubation with N°-monomethyl-L-arginine 
(200 p~molfliter, 15 rain) before coincubation experiments with 
endothelial cells and platelets were performed. 
Preparation of washed platelets. Blood was drawn from 
the antecubital vein of healthy male volunteers and anticoag- 
ulated with acid citrate dextrose at a ratio of 5:1. Platelet-rich 
plasma was obtained by centrifugation (180g, 10 rain), and 
platelets were radiolabeled by incubation with 14C-arachidonic 
acid (55 mCi/mmol, Amersham, Braunschweig) at a final 
concentration of 0.9 p~mol/liter for 3 h at 37°C. Total radio- 
activity was counted in an aliquot and tris-maleate buffer 
(200 retool/liter; pH 5.3) was added to equal volumes of 
platelet-rich plasma. Platelets were centrifuged for 10 min at 
1,600g and washed three times in citrate buffer (containing 
[in mmol/liter] sodium chloride 100, potassium chloride 5.0, 
calcium chloride 2.0, magnesium chloride 1.0, sodium citrate 
30 and [in g/liter] >glucose 0.991, bovine serum albumin 0.5; 
pH 6.5) to remove nonincorporated radioactivity. Radioactiv- 
ity was determined in the buffer used for the last washing step 
to assure complete removal of nonincorporated 14C- 
arachidonic acid and washed platelets were resuspended in
Tyrode buffer (pH 7.4). 
Platelet prostacyclin receptor desensitization. Platelet 
prostacyclin receptors were desensitized by incubation of 
platelet-rich plasma with the chemically stable prostacyclin 
analog iloprost (1, 10 or 100 nmol/liter) for 3 h at 37°C. In 
control experiments, platelets were treated identically in the 
absence of iloprost. The incubation period was terminated by 
adding equal volumes of tris-maleate buffer and washing three 
times with citrate buffer as described for the radiolabeling 
procedure. The complete removal of iloprost during the wash- 
ing procedure was confirmed by using tritiated iloprost in 
control experiments performed simultaneously. Platelets to be 
used in the adhesion experiments were coincubated with 
iloprost (10, 30 or 100 nmol/liter) and 14C-arachidonic a id. In 
preliminary experiments we had confirmed that the two pro- 
cesses did not interfere with each other {data not shown). 
The degree of platelet prostacyclin receptor desensitization 
was determined in binding experiments using 3H-iloprost as a 
radioligand. Washed platelets were resuspended in phosphate- 
buffered saline solution (pH 7.4) and the platelet count was 
adjusted to 5 × l0 s cells/ml. Nonspecific binding was measured 
by incubating 1ml of platelets with iloprost (10/xmol/liter) for 
10 rain at 30°C. Then 3H-iloprost was added at a concentration 
adapted from the predetermined dissociation constant (KD) 
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value (7.1 nmol/liter) and incubation was continued for 10 rain 
at 30°C. The reaction was terminated by rapid centrifugation 
(12,000g for 12 s) and removal of the supernatant. The 
remaining pellet was solubilized overnight in sodium hydroxide 
(0.8 mol/liter) and radioactivity of the platelet homogenate was 
measured in a scintillation counter (LKB-Wallac 1410). Total 
binding was determined in a parallel sample without addition 
of nonlabeled iloprost. Specific binding was calculated by 
subtracting nonspecific binding from total binding. Results are 
presented as binding in fmol/10 ~ platelets; receptor desensiti- 
zation is expressed as percent diminution of ~H-iloprost bind- 
ing in comparison with that of control platelets incubated with 
saline solution for 3 h (= 10(V4). 
Platelet cyclic AMP formation. Platelets were incubated 
for 3 h at 37°C in the absence or presence of iloprost (1 or 
10 nmol/liter). Preparation of washed platelets and the assur- 
ance of complete iloprost removal were carried out by using 
3H-iloprost as previously described. After the washing proce- 
dure, adenylate cyclase of the control platelets and desensi- 
tized platelets were stimulated for 0.5 to 10 rain by adding thc 
maximal effective concentration f iloprost (100 nmol/liter) as 
determined in preliminary experiments (data not shown). 
Stimulation was terminated by adding trichloroacetic acid 
(final concentration 5e4,) to each sample followed by vortexing 
and centrifugation. The supernatants were extracted three 
times with water-saturated diethyl ether, lyophilized and solu- 
bilized in radioimmunoassay (RIA) buffer. Adenylate cyclasc 
activity was assessed via measurement of cyclic AMP forma- 
tion by cyclic AMP-RIA (Amersham-Buchler, Dreieich, Ger- 
many). 
Platelet-endothelial cell adhesion. Platelet-endothelial 
cell adhesion was investigated with a method modified after 
Curwen et al. (15) using confluent human umbilical vein 
endothelial cells in 24-well plates and 14C-arachidonic a id- 
labeled washed human platelets uspended in Tyrode buffer. 
Platelet count was adjusted to 2.5 × 10 s cells/ml. All adhesion 
experiments were performed in duplicate with human umbili- 
cal vein endothelial cells of the first or second passage. Some 
endothelial monolayers were pretreated with aspirin (1 mmol/ 
liter) to prevent prostacyclin synthesis. These monolayers were 
equilibrated with aspirin-Hanks' buffered salt solution for two 
times 10 min. The incubation medium was then renewed and 
incubation was continued for 30 rain at 37°C followed by the 
removal of the supernatant and two washing steps with Hanks' 
buffered salt solution. Prostacyclin release into the medium 
was assayed by radioimmunoassay and the 6-keto-PGFl~, level 
was compared with that of control endothelial cells incubated 
with Hanks' buffered salt solution in the absence of aspirin. 
In another series of experiments designed to study the role 
of endothelium-derived r laxing factor in thrombin-induced 
platelet adhesion, monolayers were pretreated with the amino 
acid analog N<;-monomethyl-L-arginine (200 /,mol/liter) for 
15 rain at 37°C to inhibit endothelium-derived r laxing factor 
synthesis. N"-monomethyl-k-arginine was washed from the 
monolayers two times with Hanks' buffered salt solution and 
then the platelet adhesion assay was performed. For measuring 
adhesion 400 /xl of washed and labeled control or receptor 
desensitized platelets (108 platelets/well)were added to human 
umbilical vein endothelial cells monolayers, immediately fol- 
lowed by 100/xl of Tyrode buffer containing thrombin (0.08 to 
0.2 U/ml). Cells were coincubated for 15 rain at 37°C under 
gentle constant stirring. 
The endothelial cell monolayer with adhering platelets was 
gently washed three times with Hanks' buffered salt solution 
under standardized conditions to remove nonadhering platelets. 
Hydrolysis of the monolayers and adherent platelets was achieved 
by an overnight incubation with 1 N sodium hydroxide. The 
solubilized cells were placed in counting tubes, mixed with 10 ml 
scintillation cocktail (Rotiszint eco plus, Roth, Karlsruhe, Ger- 
many) and radioactivity was determined in a LKB-Wallac 1410 
scintillation counter (Pharmacia., Freiburg, Germany). 
Platelet adherence is expressed as percent adhesion. It was 
calculated as the level of radioactivity of the solubilized sample 
divided by the total radioactivity of the platelets added to each 
well, multiplied by 100. 
Statistics. The data are expressed as mean value _+ 1 SEM 
of n independent experiments, always performed in duplicate. 
Statistical analyses of dose-response r lations was carried out 
by multiple regression analysis followed by an F test. An F 
value of 0.05 was regarded as indicating a statistically signifi- 
cant difference. If repeated measures were compared, the level 
of significance was adapted according to the rule given by 
Bonferroni. The correlation between the degree of receptor 
desensitization and platelet adhesion was calculated by the 
Spearman rank correlation coetficient. 
Resu l ts  
Endothelial cell prostacyclin formation. Human umbilical 
vein endothelial cells in the first and second passage were 
characterized according to morphologic and immunohisto- 
chemical criteria. Light phase contrast microscopy demon- 
strated that the endothelial cells grew as a homogeneous 
population of closely opposed, polygonal, arge cells forming a 
monolayer with a cobblestone-like appearance. The endothe- 
lial origin of the cells was verified by the presence of von 
Willebrand factor located in cytoplasmic Weibel-Palade bod- 
ies. Cultures treated with an antibody to yon Willebrand factor 
followed by an FITC-labeled secondary antibody developed an 
intense yellow fluorescence with >95% positive staining cells. 
For further characterization e dothelial prostacyclin syn- 
thesis was studied. Prostacyclin synthesis of human umbilical 
vein endothelial cells during passage 1and 2 over a period of 
24 h on 4 consecutive days from day 2 to day 5 was determined. 
Prostacyclin content of the culture medium collected over 24 h 
was assayed by radioimmunoassay for the degradation product 
6-keto PGFI~. Prostacyclin synthesis decreased continuously 
with increasing cell density during passage 1 from 327 _+ 
51 ng/l& cells per 24 h on day 2 to 265 _+ 48, 204 +_ 42 and 
155 _+ 31 ng/106 cells per 24 h, respectively, on days 3, 4 and 5. 
During the second passage 6-keto-PGFl~ synthesis was sub- 
stantially lower at a level of 143 _+ 33 ng/106 cells per 24 h on 
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Figure 1. Alterations inthrombin-stimulated platelet adhesion (solid 
columns) after inhibition of endothelial cell nitric oxide synthase with 
N°-monomethyl-L-arginine (20 #tool/liter, 15rain [striped columns]) 
or prostacyclin synthesis by pretreatment wi h aspirin (1 mmol/liter, 
50 rain [dotted columns]), respectively. Data are shown as mean value 
(columns) _+ SEM (vertical lines) of 10 independent experiments 
performed induplicate. 
day 2, and 102 _+ 27, 81 _+ 15 and 67 + 16 ng/106 cells per 24 h, 
respectively, on days 3, 4 and 5 (n = 6, triple determinations 
each). 
Prostacyclin synthesis was stimulated inconfluent endothe- 
lial cell monolayers in passage 2by incubation with thrombin 
(0.02 to 2.0 U/ml) for 15 min at 37°C, and 6-keto-PGFl~ levels 
were measured in the incubation medium. Thrombin dose- 
dependently stimulated baseline prostacyclin production 
(11.5 _+ 0.8 ng/106 cells per 15 min, resulting in a maximal 
12.4-fold increase up to 140 _+ 12 ng/106 cells per 15 min with 
1.0 U/ml of thrombin, with 2 U/ml being equieffective. 
To study the effects of cyclooxygenase inhibition on pros- 
tacyclin synthesis human umbilical vein endothelial cells were 
preincubated with aspirin at a final concentration f 1 mmol/ 
liter for 20 min, and incubation was continued with aspirin for 
another 30 rain after exchange of the medium. The concentra- 
tion of 6-keto-PGFa, ~ decreased from 2.04 _+ 0.16 ng/500/~1 per 
Figure 2. Dose-dependent decrease in 3H-iloprost binding after incu- 
bation of human platelets with iloprost (1, 10 and 100 nmol/liter) for 
3 h. *p < 0.01 versus control. **p < 0.001 versus control. Data 
represent mean value (columns) _+ SEM (vertical lines). 1 = liter; pla. 
= platelets. 
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30 min under control conditions to 0.04 _+ 0.01 ng/500 ~1 per 
30 rain with aspirin (n = 8), indicating that prostacyclin synthesis 
was almost completely prevented (by 98.3 _+ 0.9%). Comparable 
results were obtained using indomethacin (30 ~mol/liter) as a 
cyclooxygenase inhibitor, which reduced 6-keto-PGFl~ in the 
medium by 97.9 + 2.0% (n = 3). 
Platelet-endothelial cell adhesion. Adhesion experiments 
were performed by coincubating washed human platelets with 
human umbilical vein endothelial cells grown to confluency in 
24-well plates. Therefore, platelets were radiolabeled with 
a4C-arachidonic a id for 3 h and washed three times. After the 
washing procedure 26% of the total radioactivity had been 
incorporated into the platelets with no radioactivity detectable 
in the washing buffer. To quantify the amount of arachidonic 
acid that was metabolized by platelets during thrombin stimu- 
lation, labeled platelets were activated by addition of thrombin 
(3 U/ml). Measurement of the radioactivity released from 
these platelets amounted to<4% of the radioactivity incorpo- 
rated, demonstrating that a decrease in counts during the 
adhesion experiments did not result from 14C-arachidonic a id 
metabolism. 
Co-incubation of washed platelets (10 s platelets/well) and 
confluent human umbilical vein endothelial cells during pas- 
sage 2 for 15 rain resulted in platelet adhesion of 2.7 _+ 0.3% 
to the endothelial cells. Addition of thrombin in concentra- 
tions ranging from 0.08 to 0.2 U/ml caused a dose-dependent 
increase in platelet adhesion to a maximum of 6.4 + 0.6% with 
0.2 U/ml of thrombin (n = 10) (Fig. 1). 
Endothelial thromboresistance in vivo probably is mediated 
through the endothelial cell autacoids prostacyclin and 
endothelium-derived r laxing factor. Therefore, the influence 
of these endothelial cell products on thrombin-stimulated 
platelet adhesion was measured inour model in another series 
of experiments using the respective synthesis inhibitors. Re- 
duction of endothelial prostacyclin formation by 98% during 
preincubation of human umbilical vein endothelial cells with 
aspirin did not significantly change adhesion of nonstimulated 
platelets from 2.7 _+ 0.3 to 3.1 + 0.3% (p > 0.05). However, 
thrombin-stimulated platelet adhesion was significantly en- 
hanced, resulting in adhesion of 24.2 _+ 4.3% with 0.2 U/ml of 
thrombin (n = 10) (Fig. 1). In contrast to the marked effects of 
cyclooxygenase inhibition by aspirin pretreatment, inhibition 
of endothelium-derived relaxing factor synthesis by preincuba- 
tion of the endothelial cells with the nitric oxide synthase 
inhibitor N°-monomethyl-L-arginine ex rted only minor alter- 
ations in platelet adhesion (Fig. 1). 
Platelet prostacyclin receptor desensitization. According 
to Scatchard plot analysis, the chemically stable prostacyclin 
analog iloprost dose-dependently binds to platelets with a 
maximal binding (Bmax) of 1.29 pmol/mg protein and a K D of 
39.5 nmol/liter. Long-term exposure of platelet prostacyclin 
receptors to high agonist concentrations re ulted in a time- and 
dose-dependent decrease inprostacyclin binding (Fig. 2). This 
is indicative of a decrease inbinding sites (10,11). In this study, 
platelet prostacyclin receptors were desensitized by incubation 
with iloprost at concentrations of 1, 10, or 100 nmol/liter for 
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Figure 3. Time-dependent i crease in platelet cyclic adenosine mono- 
phosphate (cAMP) after stimulation with iloprost (100 nmol/liter). 
Platelets had previously been incubated with solvent (Control) or 1 or 
10 nmol/liter of iloprost for 3 h at 37°C. Data represent mean value 
(circles) + SEM (vertical ines) of seven independent experiments 
performed in duplicate. Abbreviations as in Figure 2. 
3 h. This caused a dose-dependent decrease in prostacyclin 
binding from a control value of 361 +_ 17 to 352 = 29 (p > 
0.05), 220 _+ 15 (p < 0.01) and 181 ± 19 (p < 0.001) fmol/10 ~ 
platelets with 1, 10 and 100 nmol/liter of iloprost, respectively. 
The influence of receptor desensitization  stimulation of 
adenylate cyclase by iloprost was measured, Platelets were 
incubated for 3 h with iloprost (1 or 10 nmol/liter) followed by 
triple washout. Desensitized and control platelets were then 
stimulated with iloprost (100 nmol/liter) for 0.5 to 10 rain. 
Figure 3 shows that cyclic AMP formation was unaltered by 
incubation with low concentrations of iloprost (1 nmol/liter) 
which had not resulted in a significant decrease in binding. In 
contrast, incubation with desensitizing concentrations of ilo- 
prost (10 nmol/liter) resulted in a significant attenuation of the 
adenylate cyclase-stimulating efficacy of 100 nmol/liter of 
iloprost when compared with measurements in control plate- 
lets. 
Adhesion of receptor-desensitized platelets. Co-incubation 
of prostacyclin receptor-desensitized platelets with human 
umbilical vein endothelial cells in passage 2 resulted in a 
marked augmentation of thrombin-stimulated platelet adhe- 
sion depending on the degree of receptor desensitization. 
Whereas nonstimulatcd adhesion remained unaltered by re- 
ceptor desensitization (2.7 = 0.3% vs. 3.2 _+ 0.4%), adhesion 
was already enhanced in the presence of the lowest concentra- 
tion of thrombin (0.08 U/roll from 4.0 + 0.5% to 7.0 _- 0.5¢4 
(p < 0.05). Platelet adhesion was enhanced by a factor of 6.7 
in the presence of the highest concentration of thrombin 
(0.2 U/roll used for stimulation (p < 0.001; n = 6). These 
dose-dependent effects of thrombin on the adhesion of 
receptor-desensitized platelets are depicted in Figure 4. 
Another series of adhesion assays concerning receptor- 
desensitized platelets was performed with human umbilical 
vein endothelial cells during passage 1. which previously had 
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Figure 4. Significant augmentation of thrombin-stimulated platelet 
adhesion (solid columns) to human endothelial cells after platelet 
prostacyclin receptor desensitization (striped columns). The data 
represent mean value (columns) + SEM (vertical ines) of 10 inde- 
pendent experiments performed induplicate. *p < 0.05. **p < 0.001. 
been shown to exert he highest level of prostacyclin synthesis. 
This synthetic activity may be the reason why adhesion of 
nonstimulated platelets to endothelial cells from passage 1 
(0.7 + 0.1%) was substantially ower than that of endothelial 
cells during passage 2 (2.7 +_ 0.3%). When platelets were 
preincubated with three different concentrations of iloprost 
(10, 30 or 100 nmol/liter) for 3 h, a dose-dependent receptor 
desensitization was detectable. When the data for the iloprost- 
induced receptor desensitization and increased platelet- 
endothelial cell adhesion were plotted, a positive correlation 
for these two variables was detected for iloprost concentrations 
between 10 and 100 nmol/liter. By using a Spearman rank test 
the correlation coefficient r S was 0.71, indicating a significant 
correlation when tested two-sided (p < 0.001; Fig. 5). 
Discuss ion  
The decrease in prostacyclin binding on platelets depends 
on the incubation time and the prostacyclin dose used for 
incubating platelets in vitro. This phenomenon is similarly 
observed when chemically stable prostacyclin analogs like 
iloprost are used. In our experiments, iloprost caused a dose- 
dependent decrease in binding that was significantly lower than 
the control level. This decrease, observed at a dose of 10 
nmol/liter and unaltered with 1 nmol/liter of iloprost (data not 
shown), might be due either to a true receptor desensitization 
or to an alteration in the number of functionally incompetent 
spare receptors. Therefore, we studied the alterations in the 
receptor-linked second-messenger system and estimated ad- 
enylate cyclase activity by the amount of cyclic AMP synthe- 
sized as a result of maximal receptor-mediated stimulation. 
The decrease in prostacyclin binding correlates very well with 
the diminished adenylate cyclase activity. Platelets incubated 
with 1 nmol/liter of iloprost exerted an unaltered binding, and 
maximal stimulation of cyclic AMP synthesis by iloprost was 
not different from that of control platelets. However, diminu- 
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Figure 5. Correlation between platelet prostacyclin (PGIz) receptor 
desensitization (%)and platelet-endothelial cell adhesion (%). Plate- 
lets were incubated with saline solution (open circles) or 10 (solid 
circles), 30 (squares) or 100 nmol/liter of iloprost (triangles). Each 
point represents the mean of individual p atelet adhesion and receptor 
desensitization experiments performed in duplicate. A Spearman rank 
test revealed a correlation coefficient r S of 0.71 and indicated a
significant correlation between the two variables (p < 0.001). 
tion of binding after long-term incubation with iloprost 
(10 nmol/liter), was accompanied bya significant reduction in 
adenylate cyclase activity from that of control platelets (Fig. 3). 
These data confirm that extended exposure of platelets to 
iloprost results in a true desensitization of the prostacyclin 
receptor with a decrease inbinding and a diminished activity of 
the receptor-linked second-messenger system. 
In previous tudies, a decrease in prostacyclin binding on 
human platelets was discovered in vitro, and its physiologic 
relevance in humans was evaluated by administering infusions 
with prostacyclin and iloprost (11,16). MacDermot (11) suc- 
ceeded in explaining the obvious contradiction between very 
low plasma levels of prostacyclin and the occurrence of recep- 
tor desensitization when the infusion was administered 
through a peripheral vein. In contrast, receptor density re- 
mained unaltered when prostacyclin was infused through a 
central venous catheter, indicating the physiologic importance 
of short-term platelet exposure to high prostacyclin concentra- 
tions in its immediate vicinity. 
If prostacyclin receptor desensitization ccurs in vivo dur- 
ing infusion therapy, two questions arise. 1) Are there physi- 
ologic or pathophysiologic situations in which a receptor 
desensitization is provoked and becomes detectable ex vivo, 
and 2) is the observed receptor desensitization f any physio- 
logic importance? The first question was previously studied in 
vivo in patients with atherosclerotic disease and acute myocar- 
dial ischemia. FitzGerald et al. (17) reported in 1984 that the 
excretion of prostacyclin metabolites in urine was markedly 
elevated in patients with severe atherosclerotic vascular dis- 
ease. This is due to a precursor transfer on the level of 
arachidonic acid or prostaglandin endoperoxides PGG 2 or 
PGH 2 from activated platelets to endothelial cells (18). A 
decreased number of platelet-binding sites for prostacyclin 
from patients with spontaneous angina or acute myocardial 
ischemia was observed by Neri-Serneri et al. (19), Jaschonek et 
al. (20) and Kahn et al. (12). Although it has not yet been 
conclusively demonstrated that prostacyclin receptors are di- 
minished in patients who have increased prostacyclin metabo- 
lite excretion in urine, the evidence for this hypothesis is 
increasing. 
With respect o prostacyclin receptor desensitization either 
during infusion therapy with prostacyclin or its analogs or in 
pathophysiologic situations, the question of its physiologic 
importance is unresolved. The main purpose of this study was 
to investigate he effect of prostacyclin receptor desensitization 
on the adhesion of human platelets to human endothelial cells 
in culture. Therefore, human umbilical vein endothelial cells in 
culture were identified by light microscopy and indirect immu- 
nofluorescence for von Willebrand factor. Endothelial prosta- 
cyclin synthesis was characterized epending on cell density 
and number of passages. Because prostacyclin release into the 
incubation medium decreased markedly with successive pas- 
sages, only confluent monolayers ofpassages 1 and 2 were used 
for the adhesion experiments. Addition of thrombin resulted in 
a dose-dependent increase in endothelial prostacyclin. 
Co-incubation of washed and radiolabeled platelets with 
human umbilical vein endothelial cells resulted in very little 
platelet adhesion in the absence of thrombin. Despite the 
augmentation in prostacyclin release with increasing doses of 
thrombin added to the medium, platelet adhesion i creased in 
a dose-dependent manner, indicating the strong platelet- 
activating effect of thrombin in this model. Complete inhibition 
of endogenous prostacyclin formation by pretreating the en- 
dothelial cells with aspirin markedly enhanced stimulated 
platelet adhesion by a factor of 4. These results confirm 
published reports (4,8) stating that prostacyclin san important 
mediator of endothelial thromboresistance under conditions of 
low shear ates. The minor effects of the nitric oxide synthase 
inhibitor N°-monomethyl-L-arginine o  platelet adhesion may 
result from the fact that the adhesion experiments were 
performed uring gentle stirring and not in a flow chamber 
model. In addition, other eports (5-7) indicate that endothe- 
lial cells in culture rapidly lose their capability of synthesizing 
endothelium-derived r laxing factor. 
Platelet preincubation with iloprost caused adose-dependent 
prostacyclin receptor desensitization a d, in accordance with the 
decreased number of binding sites, we observed a marked in- 
crease in platelet adhesion to endothelial cells (Fig. 4) compara- 
ble to the enhanced adhesion to aspirin-pretreated endothelial 
cells (Fig. 1) (i.e., after complete abrogation of endothelial 
prostacyclin synthesis). Thus, desensitized platelets are less sen- 
sitive toward endogenous prostacyclin released from thrombin- 
stimulated endothelial cells. The data for the decrease inprosta- 
cyclin binding and the increase in platelet adhesion is shown in 
Figure 5 and with a p value < 0.001 in the Spearman rank 
correlation coefficient. Thus, the adhesion-preventing effect of 
endogenous prostacyclin our model is completely ost if the 
platelet prostacyclin receptor is desensitized. 
Conclusions. Our findings may have implications for the 
use of prostacyclin or iloprost, or both, in the treatment of 
patients with vascular disease, especially peripheral vascular 
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disease. Prostacyclin receptor desensitization is determined by 
the duration of treatment, dose of drug administered and 
mode of drug administration. Additionally, these effects may 
play an important pathophysiologic role if the enhanced pros- 
tacyclin release reaches receptor-desensitizing concentrations 
in the vicinity of the endothelium. 
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